<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="457">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155202</url>
  </required_header>
  <id_info>
    <org_study_id>ID2885</org_study_id>
    <nct_id>NCT05155202</nct_id>
  </id_info>
  <brief_title>Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit</brief_title>
  <acronym>ECRHIN-ICU</acronym>
  <official_title>Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit. A Multicenter Prospective Observational Study Comparing Nicardipine and Urapidil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the context of postoperative hypertension in the intensive care units, or after&#xD;
      rescusitation of hypertensive patients, intravenous antihypertensive drugs are often used.&#xD;
      Among thoses druges, Nicardipine is an effective drug, but with side effects such as&#xD;
      inhibition of pulmonary vasoconstriction. Only preclinical studies have investigated the&#xD;
      pathophysiology of this mechanism, and no clinical study have proven its clinical relevance.&#xD;
&#xD;
      The aim of this study is to establish the incidence of Nicardipine induced hypoxemia and to&#xD;
      compare it to another antihypertensive agent, Urapidil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective observational study in 8 intensive care units in three general hospitals and one&#xD;
      university hospital.&#xD;
&#xD;
      Once Nicardipine or Urapidil infusion is started, data collection of respiratory related&#xD;
      information such as type of ventilation, arterial partial pressure of oxygen, blood pressure,&#xD;
      cardiac frequency.&#xD;
&#xD;
      Statistical analysis for two qualitative variables: Group (Nicardipin or Urapidil) and&#xD;
      occurrence or worsening of hypoxemia. Secondary outcoumes analysed such as maximal drop of&#xD;
      blood pressure, evolution of the PaO2/FiO2 ratio, length of hospital stay, duration of&#xD;
      mechanical ventilation in the ventilated patients.&#xD;
&#xD;
      Analysis for different subgroups : Patients with known atelectasis, postoperative of cardiac&#xD;
      surgery, neuro-intensive care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoxemia</measure>
    <time_frame>During the twelve hours following start of drug infusion</time_frame>
    <description>Occurrence of worsening of hypoxemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of antihypertensive action</measure>
    <time_frame>During the twelve hours following start of drug infusion</time_frame>
    <description>Time before the drop of arterial systolic blood pressure below 140mmHg</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypoxemic Respiratory Failure</condition>
  <condition>Side Effect</condition>
  <condition>Hypertensive Emergency</condition>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <description>Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Nicardipine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urapidil</arm_group_label>
    <description>Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Urapidil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihypertensive Agents</intervention_name>
    <description>Administration of intravenous Nicardipine or Urapidil</description>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_label>Urapidil</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All hypertensive patients in the intensive care unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient&#xD;
&#xD;
          -  With acute arterial systolic hypertension over 140mmHg&#xD;
&#xD;
          -  Requiring intravenous administration of one of the two following drugs : Urapidil or&#xD;
             Nicardipine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient ventilated Under Nitrogen Monoxyde&#xD;
&#xD;
          -  Contraindication to Nicardipine or Urapidil&#xD;
&#xD;
          -  Refusal of the patient or his relatives&#xD;
&#xD;
          -  Patient treated for pulmonary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard DESCAMPS, MD</last_name>
    <phone>+33231063106</phone>
    <email>descamps-r@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DESCAMPS</last_name>
      <email>descamps-r@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <email>descamps-r@chu-caen.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

